Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche’s Xeloda shown to be effective in stomach cancer
Based on the results of this study, Roche plans to file for an indication in advanced stomach cancer with worldwide regulatory authorities. The drug is currently approved in
Based on the results of this study, Roche plans to file for an indication in advanced stomach cancer with worldwide regulatory authorities. The drug is currently approved in
Results of a preclinical study evaluating GX15-070 both as a monotherapy and in combination with the proteasome inhibitor bortezomib (marketed by biopharmaceutical company Millennium as Velcade) have shown
NovoSeven (Human recombinant coagulation Factor VIIa (rFVIIa)) was first authorized in the European Union in February 1996 and is currently indicated for the treatment of bleeding episodes and
This shortage, combined with a lack of training and knowledge, is also a major obstacle for health systems as they attempt to respond effectively to chronic diseases, avian
The phase I study is designed to test the safety and tolerability of ECO-4601. Up to 30 patients suffering from one of six types of cancer, and who
Othera’s topical antioxidant eye drop, OT-551, will be investigated in patients with geographic atrophy (GA), a sign of dry or atrophic age-related macular degeneration (AMD). The study will
The influenza virus used in the study was A/Vietnam/1203/04, a human pathogenic avian influenza isolated from a fatally infected patient. This virus is highly aggressive and replicates much
As a natural substance, LPT3-04 is orally available and has an excellent safety and tolerability profile. The technology is currently at a late discovery stage, and the company
Ceftaroline is a next generation, broad spectrum, cephalosporin antibiotic that combines the advantage of an enhanced gram-positive spectrum, including bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA), with broad
SuperGen has acquired all of the outstanding capital stock of Montigen for $9 million in cash and $9 million in shares of SuperGen common stock. SuperGen may pay